Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Compound application

A technology of drugs and chemical components, applied in the field of biomedicine, can solve problems such as low safety and unsatisfactory drug efficacy

Inactive Publication Date: 2018-04-20
四川睿麒源医药科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] 2. Physical carcinogens
[0018] 3. Biological carcinogens
[0031] However, the current anti-tumor drugs are not safe and effective while inhibiting the growth and proliferation of cancer cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound application
  • Compound application
  • Compound application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] Embodiment 1 antitumor experiment

[0059] Experimental animals: 18-22g clean grade male mice.

[0060] experimental method:

[0061] Set the cell density to 10 7 Each / mL S180 cell suspension was placed on ice. When inoculating, clamp the right forelimb of the mouse with tweezers and straighten it. Insert the needle from the right side of the mouse body at a distance of 1.5 cm from the armpit, and pass through the head without piercing the skin or muscle layer. When the needle reaches the armpit, inject , the volume of the injected cell suspension is 2mL / mouse, withdraw the needle quickly after the injection and release the mouse. After the inoculation, the mice were randomly divided into 4 groups, namely the model group, Pulsatilla saponin B4 (200mg / kg) group, cisplatin group (CDDP, 3mg / kg), cisplatin (3mg / kg) + Pulsatilla saponin B4 (200mg / kg) group, 13 rats in each group. 24 hours after inoculation, Pulsatilla saponin B4 group and cisplatin group were injected i...

Embodiment 2

[0063] Effect of Example 2 on in vitro hemolysis

[0064] Preparation of 2% erythrocyte suspension Take 10ml of fresh rabbit blood, put it into a Erlenmeyer flask filled with glass beads and shake it for 10 minutes, or stir the blood with a glass rod to remove fibrous protein and make it into defibrinated blood. Add 100ml of normal saline, shake well, centrifuge at 1500r / min for 15 minutes, remove the supernatant, and wash the precipitated erythrocytes with normal saline for 2-3 times according to the above method until the supernatant does not appear red. The obtained erythrocytes were mixed with physiological saline to form a 2% suspension (2 ml of erythrocytes, added with physiological saline to make 100 ml) for the test.

[0065] Take 6 clean glass test tubes of 10ml and number them. Tubes 2 to 4 are the test samples, tube 1 is the negative control tube, and tube 6 is the positive control tube (complete hemolysis control). Sequentially add Pulsatilla saponin B4 at a final...

Embodiment 3

[0072] Embodiment 3 safety evaluation

[0073] The safety of Pulsatilla saponin B4 was evaluated by acute toxicity test. The 18-25g ICR mice were randomly divided into B4 administration group and normal saline group, ten in each group. The mice in the Pulsatilla saponin B4 administration group were intraperitoneally injected with 2.5g / kg Pulsatilla saponin B4 every day, and the normal saline group was injected with the same amount of normal saline for 14 consecutive days. The mice were weighed every day to observe the survival status of the mice. The mice were sacrificed on the 14th day of administration, and the serum was extracted to detect the relevant indexes of liver and kidney function. The experimental results showed that, compared with the blank control group, there was no significant difference in the weight gain of the animals in the administration group within 14 days ( image 3 ), the animal was in good activity, good mental state, white and shiny coat, normal ur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Average tumor weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to the field of biological medicine, and in particular relates to application of pulsatilla saponin B4 to preparation of medicine for preventing and / or treating tumor. Results ofhemolysis tests show that the pulsatilla saponin B4 does not have the obvious hemolysis phenomenon during incitation by in vitro addition in rabbit 2-percent erythrocyte suspension for stimulation. According to the evaluation on toxicity of the pulsatilla saponin B4 to the in vitro cell, the condition that the pulsatilla saponin B4 does not have the obvious cell toxicity to the in vitro culturedRD cells is discovered through study. The acute toxicity tests are used for evaluating the safety of the pulsatilla saponin B4; test results show that the pulsatilla saponin B4 is safe and non-toxic.Through MTT experiments, the condition that the pulsatilla saponin B4 does not have the cell toxic effects on S180 and Lewis cancer cells, and cannot be used for inhibiting the tumor cell multiplication is discovered; but the results of mice in vivo transplantation tumor tests show that the pulsatilla saponin B4 obviously inhibits the growth of the S180 sarcoma growth in the bodies of the mice, and the anti-tumor effect is achieved in the bodies.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of compounds. Background technique [0002] Tumor is an abnormal lesion formed by the body under the action of various carcinogenic factors, a certain cell in the local tissue loses its normal regulation of its growth at the gene level, resulting in its clonal abnormal proliferation. Tumors are generally divided into two categories, benign and malignant. [0003] The etiology of tumors is mainly divided into two aspects: internal causes, weakened or destroyed immune function and genetics; external causes, chemical carcinogens such as direct carcinogens, indirect carcinogens, and non-covalent carcinogens, ionizing radiation, thermal radiation, etc. and chronic irritation) UV rays. Physical carcinogens such as bacteria, parasites, viruses, mycotoxins and other biological carcinogens. [0004] At present, it is believed that the occurrence and development of tumors are ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P35/00
CPCA61K31/704
Inventor 刘艳丽康乃馨张勇许琼明杨世林李笑然
Owner 四川睿麒源医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com